Drug Profile
Recombinant E-selectin - Novavax/NINDS
Latest Information Update: 21 Jul 2010
Price :
$50
*
At a glance
- Originator National Institute of Neurological Disorders and Stroke; Novavax
- Class Recombinant proteins
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Myocardial infarction; Stroke
Most Recent Events
- 10 Aug 2007 This programme is still in active development
- 24 Sep 2002 Preclinical trials in Stroke in USA (unspecified route)